Intrapulmonary Pharmacokinetics of Antibiotics
Comparison of the Intrapulmonary and Plasma Concentrations of Telithromycin and Azithromycin in Healthy Adult Subjects
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
Arizona
-
Phoenix, Arizona, United States, 85006
- Pulmonary Associates PA
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Between 18 and 55 years, inclusive, of age
- No history of smoking within the last 1 year
- Body weight within +/- 15% of the Metropolitan Life Insurance Company tables
- No clinically important abnormalities in the medical history or physical exam
- Female subjects of childbearing potential must have a negative pregnancy test
- Female subjects of childbearing potential must use reliable methods of birth control
Exclusion Criteria:
- Allergy to telithromycin, azithromycin, or any macrolide antibiotic
- Allergy or serious adverse reactions to benzodiazepines or lidocaine
- History of renal, gastrointestinal, or liver disease
- Significant hypertension
- Clinically significant heart or pulmonary diseases
- History of drug or alcohol dependence within 12 months of study entry
- Positive pregnancy test
- Currently breast feeding
- Use of any drug within 2 weeks of study entry
- Received an investigational drug within 30 days of study entry
Study Plan
How is the study designed?
Design Details
- Allocation: Non-Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Plasma and intrapulmonary drug concentrations and pharmacokinetic parameters
Time Frame: 7 days
|
7 days
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
How long does the study antibiotics get into the fluids and cells of the lung.
Time Frame: 7 days
|
7 days
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Keith A. Rodvold, Pharm.D., University of Illinois at Chicago
- Principal Investigator: Mark H. Gotfried, M.D., Pulmonary Associates, PA
- Principal Investigator: Larry H. Danziger, Pharm.D., University of Illinois at Chicago
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 2005-0748
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.